Pathological scars may soon face a high-tech adversary: tiny, dissolving needles made from water-rich gels that can punch through dense scar tissue and release treatment precisely where it is needed. A review published in Materials Today Bio examines how hydrogel microneedles could transform the management of hypertrophic scars and keloids by combining mechanical remodeling, targeted drug delivery and “smart” responses to the chemical signals of diseased tissue. Unlike conventional creams, which often struggle to cross scarred skin, or steroid injections, which can be painful and cause skin atrophy, the new patches are designed to create microscopic pathways into the dermis while delivering drugs gradually and locally. The technology remains largely in the research and clinical-validation stage, but the review describes a rapidly expanding field that could eventually bring personalized scar treatment closer to the patient’s home.
Scars form when the normal repair process fails to shut down. After an injury, immune cells release signals that activate fibroblasts, the connective-tissue cells responsible for producing collagen. In pathological scarring, inflammation persists, fibroblasts remain overactive and collagen accumulates in thick, disorganized bundles. Hypertrophic scars rise above the skin but remain within the original wound, while keloids extend beyond the wound margins and can continue invading nearby healthy tissue. Both may itch, hurt, restrict movement or cause lasting psychological distress. Existing treatments—including corticosteroids, cryotherapy, lasers and radiotherapy—can help, but each has limitations involving recurrence, pain, cost, pigmentation changes, tissue damage or restricted use. The review argues that the defining problem is not simply finding a more powerful drug; it is getting the right dose into the right layer of abnormal tissue without harming healthy skin.
Hydrogel microneedles address that problem through a deceptively simple architecture. An array of microscopic projections is formed from a hydrogel, a three-dimensional polymer network capable of absorbing and retaining large amounts of water. When pressed against the skin, the needles cross the stratum corneum—the tough outer barrier that blocks many medicines—without reaching the depth associated with conventional injections. Once inside the tissue, the hydrogel may swell, dissolve or slowly degrade, releasing its cargo into the surrounding dermis. The microneedles can also create microchannels through dense collagen bundles, increasing local permeability and disrupting the mechanical environment that helps maintain fibrosis. Because the needles are only micrometers wide, the procedure can be minimally invasive and substantially less painful than a hypodermic injection. The backing layer supports the array, keeps it aligned with the skin and may also function as a drug reservoir, adhesive or protective barrier.
The choice of polymer determines whether a patch bends, breaks, swells, dissolves or releases its payload over minutes, hours or days. Natural materials such as hyaluronic acid, gelatin, chitosan, silk fibroin and alginate are attractive because they are generally biocompatible and can support tissue repair. Their weakness is that they may lack the strength required to penetrate thick, hardened scars. Synthetic polymers such as polyvinyl alcohol, polyvinylpyrrolidone and polyethylene glycol offer more predictable mechanical behavior and processing, although they may be less biologically active or more difficult to degrade. Researchers therefore often combine materials or create double networks. A gelatin methacryloyl/polyethylene glycol diacrylate patch, for example, uses interlocking polymer networks to improve strength and slow biodegradation. In one cited study, a compound betamethasone patch reduced scar elevation and collagen abnormalities in animal models with an effect comparable to conventional injections.
How the hydrogel network is cross-linked is equally important. Physical cross-linking relies on reversible interactions such as hydrogen bonds, hydrophobic associations, electrostatic attraction or repeated freeze–thaw cycles. These methods can avoid potentially toxic chemical cross-linkers and produce materials capable of responding dynamically to their surroundings, but the resulting networks may weaken under mechanical stress. Chemical cross-linking creates covalent bonds between polymer chains, producing a tougher and more stable structure that can survive repeated swelling. Photopolymerization, Schiff-base reactions and ester bonds are among the strategies described in the review. The fabrication process also shapes performance. Conventional micromolding is relatively inexpensive and suitable for scaling, while digital-light-processing and direct-ink-writing 3D printing can produce customized geometries, sharp tips and complex arrays without a fixed mold. In-situ forming systems go further by creating microneedle-like hydrogel structures directly on a carrier or biological surface when exposed to a trigger.
The most futuristic patches are not passive drug depots. They are engineered to read the biochemical state of damaged tissue and respond accordingly. A pH-sensitive network can remain relatively stable in one environment but loosen or break in an acidic wound, releasing its cargo. Glucose-responsive systems use glucose oxidase or phenylboronic acid chemistry to adjust swelling and drug release as sugar levels change, a principle already explored for insulin delivery. Reactive-oxygen-species-responsive patches are particularly relevant to pathological scars, where oxidative stress can be elevated. Chemical groups such as thioketals, thioethers, phenylboronic acid and diselenide bonds can be oxidized or cleaved by excess reactive oxygen species, causing the network to swell, degrade or release an antioxidant drug. In one highlighted system, microneedles delivered asiatic-acid nanoparticles that responded to the high-oxidative-stress environment of hypertrophic scars, scavenging reactive oxygen species while suppressing inflammation, fibroblast proliferation and excess collagen deposition.
External signals can provide another layer of control. Light-responsive materials may use ultraviolet, visible or near-infrared energy to generate heat or reactive oxygen species, changing the hydrogel’s structure or activating photodynamic therapy. The review describes patches carrying photosensitizers that generate reactive oxygen species under illumination, a strategy capable of killing bacteria or damaging scar-forming fibroblasts. Ultrasound can activate piezoelectric or sonosensitizing components, while electrical and magnetic fields can influence swelling, movement or release. These capabilities raise the possibility of treatment schedules that are spatially and temporally controlled: an early burst of an anti-inflammatory compound followed by a slower release of an anti-fibrotic agent, or activation only when a clinician—or potentially a wearable device—delivers a specific stimulus. Core-shell and layered designs are central to this approach because separate regions of a single patch can carry different drugs and dissolve at different rates.
The biological effects of these devices extend beyond drug delivery. Microneedle puncture itself produces a controlled mechanical stimulus that can alter signaling in fibroblasts. Mechanical forces are transmitted through pathways involving integrins, focal adhesion kinase and the transcriptional regulators YAP and TAZ, which connect physical tension with cell metabolism, proliferation and extracellular-matrix production. Carefully designed arrays may reduce the contractile forces that keep a scar stiff while encouraging healthier collagen remodeling. The swelling hydrogel can improve hydration in dry, hardened tissue, and the microchannels may help exchange oxygen and inflammatory molecules. Meanwhile, payloads can target the molecular drivers of fibrosis. Corticosteroids suppress inflammation and fibroblast activity; 5-fluorouracil and bleomycin inhibit proliferating scar cells; plant-derived compounds such as salvianolic acid B, glabridin and asiaticoside act on oxidative stress and pro-fibrotic signaling; and exosomes or small interfering RNA can modify cellular behavior more directly. In animal studies, these combinations have reduced scar thickness, collagen deposition, erythema and expression of markers such as transforming growth factor beta and alpha-smooth muscle actin.
Human evidence is beginning to emerge, but it is far thinner than the impressive laboratory literature. A randomized study comparing dissolving 5-fluorouracil microneedles with intralesional injections for keloids found that injections reduced scars more quickly during treatment, whereas the difference was no longer statistically significant three months after treatment ended. The microneedle group experienced less pain, with temporary pigmentation changes and superficial peeling resolving spontaneously. In another clinical trial, triamcinolone-loaded dissolving microneedles reduced keloid volume, although some recurrence followed treatment discontinuation. A human trial of siRNA-loaded microneedles for postoperative scars reported a greater reduction in scar volume than silicone sheets after 60 days. Yet dense keloids remain a formidable obstacle: even long microneedles may reach only the superficial dermis, leaving deeper fibrotic tissue untreated. The review estimates that only a small fraction of hydrogel microneedle research has reached human trials, while most studies remain in vitro or in animals.
That gap highlights why the technology is promising but not yet a ready-made cure. Hydrogel microneedles must be strong enough to pierce hardened scars without snapping, yet soft and absorbent enough to swell or dissolve after insertion. High drug loading can weaken needle tips, while fragile proteins, nucleic acids and growth factors may lose activity during storage or sterilization. Manufacturing uniform medical-grade arrays at scale, validating long-term safety and establishing consistent treatment protocols will require substantial investment and multicenter trials. Scars also vary dramatically according to location, age, depth, inflammation and patient biology, making a single universal patch unlikely to work equally well for everyone. The researchers envision artificial intelligence helping to close that gap by predicting how polymer combinations will behave, simulating needle penetration and drug diffusion, and matching patch geometry and formulation to an individual scar. With 3D scanning and customized printing, future devices could be shaped to irregular scars and programmed for patient-specific release schedules. For now, hydrogel microneedles represent an unusually versatile bridge between materials science and dermatology—one that may turn scar treatment from repeated, painful intervention into a precise, adaptive and potentially self-administered therapy.
Subject of Research: Hydrogel microneedles for minimally invasive, stimuli-responsive treatment and prevention of pathological scars, including hypertrophic scars and keloids.
Subject of Research: Technology and Engineering
Article Title: Hydrogel microneedles functioning in pathological surroundings: where soft materials overcome hard scars
Article References: Lei, K., Xu, Z., Gong, D., Wang, W., Cheng, J., Li, J., Pang, X., & Jia, Z. (2026). Hydrogel microneedles functioning in pathological surroundings: where soft materials overcome hard scars. Materials Today Bio, 40, Article 103571. https://doi.org/10.1016/j.mtbio.2026.103571
Image Credits: AI Generated
DOI: 10.1016/j.mtbio.2026.103571
Keywords: hydrogel microneedles, pathological scars, hypertrophic scars, keloids, controlled drug delivery, stimuli-responsive biomaterials, scar remodeling, personalized medicine
Cite Scienmag News
APA
MLA
Chicago
SCIENMAG. (August 28, 2026). Hydrogel Microneedles Navigate Diseased Tissue and Overcome Rigid Scars. https://scienmag.com/hydrogel-microneedles-navigate-diseased-tissue-and-overcome-rigid-scars/
SCIENMAG. “Hydrogel Microneedles Navigate Diseased Tissue and Overcome Rigid Scars.” Scienmag, 28 August 2026, https://scienmag.com/hydrogel-microneedles-navigate-diseased-tissue-and-overcome-rigid-scars/. Accessed 28 August 2026.
SCIENMAG. “Hydrogel Microneedles Navigate Diseased Tissue and Overcome Rigid Scars.” Scienmag. August 28, 2026. https://scienmag.com/hydrogel-microneedles-navigate-diseased-tissue-and-overcome-rigid-scars/
Copy citation
Download RIS
Tags: clinical validation of microneedle patchesclinical validation of microneedle therapiesdissolving microneedle technologyfuture of scar treatment innovationshydrogel microneedleshypertrophic and keloid scar managementlocalized drug release in dermatologylocalized drug release in skinmechanical remodeling of scar tissueminimally invasive scar managementminimally invasive scar therapyovercoming dense scar tissuepersonalized scar treatmentpersonalized wound healing solutionsscar tissue remodelingsmart responsive biomaterialssmart responsive scar therapiestargeted drug delivery for scar treatmenttargeted drug delivery for scarstreatment of hypertrophic scars and keloidswater-rich gel patch innovations
